Immix Biopharma, Inc. announced dosing of an additional patient in its ongoing Phase 1b/2a IMX-110 monotherapy clinical trial. Positive safety data enabled continued dosing of previously enrolled patients. In January 2023, the seventeenth patient was dosed with IMX-110 to-date.

IMX-110 clinical trial data is expected to be released on a rolling basis beginning in first quarter 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110.